These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 30858732)
1. Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome. Chirchiglia D; Chirchiglia P; Marotta R; Gallelli L Int Med Case Rep J; 2019; 12():39-42. PubMed ID: 30858732 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial. Ottaviani G; Rupel K; Gobbo M; Poropat A; Zoi V; Faraon M; Di Lenarda R; Biasotto M Clin Oral Investig; 2019 Jun; 23(6):2743-2750. PubMed ID: 30361792 [TBL] [Abstract][Full Text] [Related]
3. Clinical and therapeutic experience in twenty eight patients with burning mouth syndrome. Santoro V; Caputo G; Peluso F Minerva Stomatol; 2005 Sep; 54(9):489-96. PubMed ID: 16215533 [TBL] [Abstract][Full Text] [Related]
4. Burning mouth syndrome: a review of therapeutic approach. Nosratzehi T J Complement Integr Med; 2021 Dec; 19(1):83-90. PubMed ID: 34881535 [TBL] [Abstract][Full Text] [Related]
6. Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study. Scaturro D; Asaro C; Lauricella L; Tomasello S; Varrassi G; Letizia Mauro G Pain Ther; 2020 Jun; 9(1):319-326. PubMed ID: 31863365 [TBL] [Abstract][Full Text] [Related]
7. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. Schweiger V; Martini A; Bellamoli P; Donadello K; Schievano C; Balzo GD; Sarzi-Puttini P; Parolini M; Polati E CNS Neurol Disord Drug Targets; 2019; 18(4):326-333. PubMed ID: 30827269 [TBL] [Abstract][Full Text] [Related]
8. Burning mouth syndrome after taking clonazepam. Culhane NS; Hodle AD Ann Pharmacother; 2001; 35(7-8):874-6. PubMed ID: 11485137 [TBL] [Abstract][Full Text] [Related]
9. Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol. Femiano F; Lanza A; Buonaiuto C; Gombos F; Nunziata M; Cuccurullo L; Cirillo N Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jan; 105(1):e22-7. PubMed ID: 18155597 [TBL] [Abstract][Full Text] [Related]
10. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. Stochino Loi E; Pontis A; Cofelice V; Pirarba S; Fais MF; Daniilidis A; Melis I; Paoletti AM; Angioni S Int J Womens Health; 2019; 11():443-449. PubMed ID: 31496832 [TBL] [Abstract][Full Text] [Related]
12. Correlation between Burning Mouth Syndrome and Anxiety in the Elderly Inmates of Sanitaria in Tehran. Bakhtiari S; Khalighi HR; Azimi S; Alavi K; Ayoobi Valoogerdi H; Namazi Z J Dent Res Dent Clin Dent Prospects; 2010; 4(2):37-41. PubMed ID: 22991594 [TBL] [Abstract][Full Text] [Related]
13. Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome. Paladini A; Varrassi G; Bentivegna G; Carletti S; Piroli A; Coaccioli S Pain Res Treat; 2017; 2017():1486010. PubMed ID: 28875041 [TBL] [Abstract][Full Text] [Related]
14. Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases. Chirchiglia D; Chirchiglia P; Signorelli F Neurol Neurochir Pol; 2018; 52(1):44-47. PubMed ID: 29157725 [TBL] [Abstract][Full Text] [Related]
15. Association of anxiety, depression, and stress with burning mouth syndrome: a case-control study. Malta CEN; Costa FWG; Dias CC; Carlos ACAM; Sousa FB; Silva PGB; Teófilo CR Gen Dent; 2021; 69(4):46-52. PubMed ID: 34185668 [TBL] [Abstract][Full Text] [Related]
16. Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study. Barry A; O'Halloran KD; McKenna JP; McCreary C; Downer EJ J Oral Pathol Med; 2018 Feb; 47(2):158-165. PubMed ID: 29194773 [TBL] [Abstract][Full Text] [Related]
17. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. López-D'alessandro E; Escovich L Med Oral Patol Oral Cir Bucal; 2011 Aug; 16(5):e635-40. PubMed ID: 20711135 [TBL] [Abstract][Full Text] [Related]
18. Interventions for the treatment of burning mouth syndrome. Zakrzewska JM; Glenny AM; Forssell H Cochrane Database Syst Rev; 2001; (3):CD002779. PubMed ID: 11687027 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of moclobemide in burning mouth syndrome: a nonrandomized, open-label study. Pekiner FN; Gumru B; Ozbayrak S J Orofac Pain; 2008; 22(2):146-52. PubMed ID: 18548844 [TBL] [Abstract][Full Text] [Related]